Gen. of transgenic chickens using a lentiviral approach

Information

  • Research Project
  • 6992369
  • ApplicationId
    6992369
  • Core Project Number
    R44GM070158
  • Full Project Number
    2R44GM070158-02
  • Serial Number
    70158
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/4/2004 - 20 years ago
  • Project End Date
    7/31/2007 - 17 years ago
  • Program Officer Name
    PORTNOY, MATTHEW
  • Budget Start Date
    8/1/2005 - 19 years ago
  • Budget End Date
    7/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/1/2005 - 19 years ago

Gen. of transgenic chickens using a lentiviral approach

[unreadable] DESCRIPTION (provided by applicant): [unreadable] Currently, chimeric chickens are made by injecting blastodermal cells or chicken embryonic stem cells into stage X recipient embryos, but the frequency and the level of chimerism is variable and not predictable. We are developing a universal recipient that contributes minimally, so that the contribuion of donor dervied celld to the resulting chimera is constantly high and predictable. [unreadable] [unreadable] In phase I of this SBIR project, a lentiviral vector for the universal recipient chicken line and for a GFP control line was generated and evaluated by transducing stage X chicken embryos with a lentiviral vector. The results clearly demonstrated the feasibility of a lentiviral approach for the establishment of the universal recipient transgenic chicken lines. [unreadable] [unreadable] In phase II of this grant application, we plan to generate the universal recipient chicken lines using the lentiviral approach. The project is unique and innovative because it seeks to establish a reliable and reproducible method of compromising the recipient embryos to consistently yield high-grade chimeras and allow the production of significant amounts of protein per egg in a short period of time. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    796237
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:796237\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORIGEN THERAPEUTICS
  • Organization Department
  • Organization DUNS
    026167994
  • Organization City
    Emeryville
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94608
  • Organization District
    UNITED STATES